PRDX6过表达增强肺癌细胞系A549的迁移和侵袭
|
摘要
目的探讨PRDX6过表达对肺癌细胞系A549迁移性及侵袭性的影响。方法 1)体外培养人肺癌细胞系A549,分为空白组、转染PRDX6组、转染空质粒组。2)Western blot检测细胞PRDX6蛋白表达;3)Transwell小室法检测细胞的迁移性及侵袭性。结果 1)转染PRDX6组PRDX6蛋白表达较空白组及转染空的质粒组明显增高(均P<0.05);2)转染PRDX6组迁移性及侵袭性较空白组及转染空质粒组显著增高(P<0.05)。结论 PRDX6的高表达增强肺癌细胞系A549的迁移性及侵袭性。
Objective To investigate the effect of over-expression of PRDX6 on migration and invasiveness of lung cancer cell line A549. Methods 1)In vitro cultured human lung cancer cells A549,divided into blank group for not transfection,experimental group for transfection PRDX6 and control group for empty plasmid transfection;2)The expression of PRDX6 in each group was detected by Western blot;3)The migration and invasion of cells in each group were assessed by transwell chamber assays. Results 1)The expression of PRDX6 protein in the experimental group was significantly higher than those in the blank and the control group(P<0.05).2) the capacity of A549 cells migration and invasion in the experimental group was the highest among the three groups(P<0.05).Conclusions The over-expression of PRDX6 can enhance the migration and invasion of A549 cells.
Objective To investigate the effect of over-expression of PRDX6 on migration and invasiveness of lung cancer cell line A549. Methods 1)In vitro cultured human lung cancer cells A549,divided into blank group for not transfection,experimental group for transfection PRDX6 and control group for empty plasmid transfection;2)The expression of PRDX6 in each group was detected by Western blot;3)The migration and invasion of cells in each group were assessed by transwell chamber assays. Results 1)The expression of PRDX6 protein in the experimental group was significantly higher than those in the blank and the control group(P<0.05).2) the capacity of A549 cells migration and invasion in the experimental group was the highest among the three groups(P<0.05).Conclusions The over-expression of PRDX6 can enhance the migration and invasion of A549 cells.
引文
[1] Wei S, Tian J, Song X, et al. Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database[J]. Cancer Res Clin Oncol, 2017, 144:1-11.
[2] 张成林, 李建远. 抗氧化蛋白Peroxiredoxin6研究进展[J]. 医学研究杂志, 2010, 39:121-123.
[3] Yun HM, Park KR, Lee HP, et al. PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities.[J]. Free Radic Biol Med, 2014, 69:367-376.
[4] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA[J]. CA Cancer J Clin, 2012, 62:10-29.
[5] Kanwal R, Gupta S. Epigenetic modifications in cancer[J]. Clin Genet, 2012, 81:303-311.
[6] Rostila A, Puustinen A, Toljamo T, et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure.[J]. Lung Cancer, 2012, 77:450-459.
[7] Li DQ, Wang L, Fei F, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry[J]. Proteomics, 2006, 6:3352-3368.
[8] Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.[J]. Proteomics, 2004, 4:3246-3267.
[9] 曾跃平,刘杰,王宝等.过氧化物酶Peroxiredoxin家族与肿瘤关系研究进展 [J].癌症进展,2010,8:164-166.
[10] Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer[J]. Int J Cancer, 2004, 111:514-521.
[11] Memon AA, Chang JW, Oh BR, et al. Identification of differentially expressed proteins during human urinary bladder cancer progression[J]. Cancer Detect Prev, 2005, 29: 249-255.
[12] Zhang C, Ye L, Guan S, et al. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer[J]. Tumor Biol, 2014, 35:2047-2051.
[13] Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.[J]. Breast Cancer Res, 2007, 9:1-15.
[14] 韩晓红沈胤晨, 石远凯. 肺癌个体化靶向治疗伴随诊断的新进展[J]. 中华检验医学杂志, 2015, 38:649-652.
[15] 赵军肺癌靶向治疗进展[J].临床外科杂志,2016,24:514-517.
[2] 张成林, 李建远. 抗氧化蛋白Peroxiredoxin6研究进展[J]. 医学研究杂志, 2010, 39:121-123.
[3] Yun HM, Park KR, Lee HP, et al. PRDX6 promotes lung tumor progression via its GPx and iPLA2 activities.[J]. Free Radic Biol Med, 2014, 69:367-376.
[4] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA[J]. CA Cancer J Clin, 2012, 62:10-29.
[5] Kanwal R, Gupta S. Epigenetic modifications in cancer[J]. Clin Genet, 2012, 81:303-311.
[6] Rostila A, Puustinen A, Toljamo T, et al. Peroxiredoxins and tropomyosins as plasma biomarkers for lung cancer and asbestos exposure.[J]. Lung Cancer, 2012, 77:450-459.
[7] Li DQ, Wang L, Fei F, et al. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry[J]. Proteomics, 2006, 6:3352-3368.
[8] Castagna A, Antonioli P, Astner H, et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431.[J]. Proteomics, 2004, 4:3246-3267.
[9] 曾跃平,刘杰,王宝等.过氧化物酶Peroxiredoxin家族与肿瘤关系研究进展 [J].癌症进展,2010,8:164-166.
[10] Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer[J]. Int J Cancer, 2004, 111:514-521.
[11] Memon AA, Chang JW, Oh BR, et al. Identification of differentially expressed proteins during human urinary bladder cancer progression[J]. Cancer Detect Prev, 2005, 29: 249-255.
[12] Zhang C, Ye L, Guan S, et al. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer[J]. Tumor Biol, 2014, 35:2047-2051.
[13] Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer.[J]. Breast Cancer Res, 2007, 9:1-15.
[14] 韩晓红沈胤晨, 石远凯. 肺癌个体化靶向治疗伴随诊断的新进展[J]. 中华检验医学杂志, 2015, 38:649-652.
[15] 赵军肺癌靶向治疗进展[J].临床外科杂志,2016,24:514-517.